BioMarin Pharmaceutical Inc. (BMRN) Stock Price & How to Invest

Last updated November 2026

Short answer

BioMarin (BMRN) is a large-cap rare-disease biopharma whose profile now hinges on scaling Voxzogo for achondroplasia and integrating the roughly $4.8B Amicus acquisition, so investors are essentially buying a portfolio of high-priced treatments for very small patient populations. As of October 16, 2026 the shares sit near $55, down about 7% in 2026 despite a strong second quarter, as new achondroplasia competition and Alesta deal charges weigh on sentiment. You can hold it directly or as part of a healthcare or rare-disease theme rather than as a broad-market proxy.

BMRN stock price

As of 2026-11-16, BioMarin Pharmaceutical Inc. (BMRN) last closed at $57.99, up 6.5% over the past year. Over the past 52 weeks it has traded between $49.67 and $70.24.

BMRN last close
$57.99
1 day
+1.33%
1 month
+6.05%
1 year
+6.48%
52-week range
$49.67 to $70.24
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or BioMarin Pharmaceutical Inc.'s investor relations page. Walnut is informational, not investment advice.

BMRN key stats

At $57.99 on November 16, 2026, BioMarin Pharmaceutical Inc. (BMRN) has a market cap of $11.2B.

Market cap
$11.2B
P/E (forward)
9.1
Price to book
1.8
Beta
0.23

Market cap, P/E and yield are measured at the $57.99 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with BioMarin Pharmaceutical Inc. (BMRN)?

The last two weeks for BioMarin Pharmaceutical Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • BMRN closed at $57.99 on November 16, 2026, up 1.4% over the past five trading days (from $57.18).
  • On November 3, 2026, BioMarin Pharmaceutical Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, JP Morgan lowered its target to $86.00 from $87.00 (Overweight).
  • On November 3, 2026, Morgan Stanley lowered its target to $119.00 from $122.00 (Overweight).
  • On November 3, 2026, Oppenheimer lowered its target to $94.00 from $97.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

BioMarin Pharmaceutical Inc. (BMRN) latest quarter

BioMarin reported revenue of $1.0 billion for Q3 2026, up 32% from a year earlier (BioMarin, Nov 2, 2026).

Revenue
$1.0 billion
up 32% from a year earlier
Diluted EPS (GAAP)
-$0.63
n/a
VOXZOGO
$245 million
up 12% from a year earlier

Source: BioMarin Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does BioMarin Pharmaceutical Inc. (BMRN) do?

BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio, and in October it presented five-year Phase 3 data showing durable efficacy for Pombiliti plus Opfolda. On September 1, 2026 it closed a smaller deal for Alesta Therapeutics, whose lead program ALE1 is an oral small molecule in a Phase 1/2a trial for hypophosphatasia, a rare genetic bone disease. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down.

The investment picture is one of steady, high-margin growth from a diversified set of rare-disease franchises rather than a single blockbuster bet. BioMarin generated about $3.2 billion of revenue in 2025 and had guided 2026 revenue to roughly $3.83 to $3.93 billion, an acceleration driven largely by the Amicus products and continued Voxzogo uptake; analysts' consensus sits near $3.91 billion. The first full quarter with Amicus showed it: Q2 2026 revenue rose about 20% to roughly $990 million and non-GAAP EPS of $1.20 beat the $0.95 consensus, after a Q1 miss ($0.76 against $0.91). GAAP profit is thin, with trailing net income of about $73 million, because of deal and write-down charges, and BioMarin has said the Alesta deal brings $283 million of acquired in-process R&D into Q3, an expected $1.50 hit to Q3 adjusted EPS.

The stock has not followed the revenue. As of October 16, 2026 BMRN closed near $55.06, down about 7% year to date and 14% over the past month, though up about 4% over one year, for a market cap near $10.7 billion. The bull case is durable pricing power, orphan-drug exclusivity, and Voxzogo label expansion; the bear case is heavy reliance on a few products, integration risk from the Amicus deal, and rising competition in achondroplasia, where the FDA granted priority review to BridgeBio's filing in October. Q3 2026 results are scheduled for October 26, 2026.

What's driving BioMarin Pharmaceutical Inc. (BMRN)?

1. Voxzogo growth engine

Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. BioMarin is pursuing label expansions and additional indications, including hypochondroplasia, and presented new data on both conditions at the American Society for Bone and Mineral Research meeting in October 2026. The franchise now faces a sharper test: the FDA granted priority review to BridgeBio's achondroplasia drug filing in October, so Voxzogo's lead could narrow sooner than the market expected.

2. Amicus acquisition and portfolio breadth

The roughly $4.8 billion Amicus deal, completed in April 2026, added Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease, and those products helped lift Q2 2026 revenue about 20% year over year. Five-year Phase 3 data presented in October showed durable efficacy for Pombiliti plus Opfolda. Management expected the deal to be slightly dilutive to 2026 non-GAAP earnings but accretive starting in 2027, and consensus EPS of about $6.51 for 2027 (versus about $4.63 for 2026) assumes that accretion arrives.

3. Enzyme therapy base and margins

Established enzyme replacement products such as Vimizim, Naglazyme and Palynziq provide a stable, high-margin cash-generating base with long orphan-drug exclusivity. This recurring revenue funds research and the pipeline, and trailing operating cash flow was about $857 million. Double-digit growth across enzyme therapies contributed to record 2025 revenue, though the Amicus purchase also lifted debt to about $4.2 billion against roughly $874 million of cash.

4. Pipeline and business development

BioMarin is advancing internal programs including BMN 333, BMN 351 and BMN 401, alongside further Voxzogo indications. It added ALE1, an oral hypophosphatasia candidate, through the Alesta acquisition that closed September 1, 2026, at the cost of a $283 million in-process R&D charge in Q3, and in October announced a partnership with Profluent on AI-designed enzyme therapies. These earlier-stage assets offer longer-term upside if trials read out well. The company has also shown willingness to prune assets, as with the Roctavian withdrawal, to focus resources.

What are the risks to BioMarin Pharmaceutical Inc. (BMRN)?

Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is building, including Ascendis Pharma's TransCon CNP and BridgeBio's achondroplasia drug, which received FDA priority review in October 2026, plus multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk and roughly $4.2 billion of debt, the Alesta deal brings a $1.50 hit to Q3 adjusted EPS, and the Roctavian withdrawal shows that expensive programs can fail commercially. GAAP earnings are thin (a trailing P/E near 149), so the low forward multiple only holds if guided growth and accretion materialize. Analysts have been trimming targets, for example UBS cutting to $88 from $114 in October while keeping a Buy rating.

What is the BioMarin Pharmaceutical Inc. (BMRN) forecast?

27 analysts publish price targets on BMRN, averaging $90.78 as of November 2026, or +56.5% against the $57.99 share price on November 16, 2026. The published targets run from $60.00 to $120.00, a moderate spread, and the ratings split 21 buy, 7 hold, 0 sell. Over the last six months there have been 3 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BMRN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is BMRN a buy or a sell?

We give no verdict on BioMarin Pharmaceutical Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Voxzogo growth engine. Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. The most optimistic published target, $120.00, assumes this works close to its best case.

The case against. Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. The most pessimistic target, $60.00, is roughly what BMRN is worth if this bites instead.

Read the full bull and bear case on BMRN, including what would have to change to break either one. Walnut is not an investment adviser.

Has BioMarin Pharmaceutical Inc. (BMRN) split its stock?

No. BioMarin Pharmaceutical Inc. (BMRN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is BioMarin Pharmaceutical Inc. (BMRN) valued?

Market cap, P/E and dividend yield at today's price are in the BMRN key stats above. The business figures below come from BioMarin Pharmaceutical Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$3.41B
  • Q2 2026 revenue: ~$990M, up ~20% YoY
  • Q2 2026 non-GAAP EPS: $1.20 vs $0.95 consensus
  • Net income (TTM, GAAP): ~$73M (~2% net margin)
  • 2026 revenue consensus: ~$3.91B (company guide ~$3.83B to $3.93B)

As of October 2026: At about $55 per share on October 16, 2026, BioMarin trades near 8 times forward earnings and about 3 times trailing sales, while the GAAP trailing P/E near 149 reflects deal and write-down charges rather than the underlying business. The market is pricing meaningful risk to Voxzogo from new achondroplasia entrants. The 27 analysts in Yahoo's consensus carry a mean target near $92, and Q3 2026 results on October 26 will include the expected $1.50 Alesta charge to adjusted EPS.

What themes does BioMarin Pharmaceutical Inc. (BMRN) fit?

These are the investment theses BMRN naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with BioMarin Pharmaceutical Inc. (BMRN)?

Rare-disease and orphan-drug specialists

Companies focused on genetic and rare diseases such as Ultragenyx, Alnylam, Sarepta Therapeutics and Vertex Pharmaceuticals compete for the same patient populations, physicians and pipeline assets, and set the market's expectations for orphan-drug growth and pricing.

Large-cap enzyme and metabolic players

Sanofi (Genzyme), Takeda and AstraZeneca's Alexion unit market competing enzyme replacement and Fabry or Pompe therapies, including Fabrazyme and Replagal, putting them in direct competition with BioMarin's core enzyme franchises and the acquired Amicus products. Alexion also markets Strensiq for hypophosphatasia, the condition targeted by BioMarin's newly acquired ALE1 program.

Achondroplasia challengers

Voxzogo's leadership in achondroplasia faces emerging competition, most notably Ascendis Pharma's TransCon CNP and BridgeBio's achondroplasia drug, which received FDA priority review in October 2026. Their progress could pressure BioMarin's fastest-growing product over time.

What stocks are similar to BioMarin Pharmaceutical Inc. (BMRN)?

Other names that sit close to BMRN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in BioMarin Pharmaceutical Inc. (BMRN)

There are three common ways to get BMRN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BMRN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BMRN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on BioMarin Pharmaceutical Inc. (BMRN)

BMRN is a profitable, growing rare-disease specialist whose value rests on Voxzogo momentum and successful Amicus integration, offset by pipeline, pricing and competitive risk. In October 2026 the stock trades near 8 times forward earnings, a low multiple for a company with revenue up about 20% in its latest quarter, which shows how much the market discounts the threat to Voxzogo.

More on BioMarin Pharmaceutical Inc. (BMRN)

Whether BMRN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BMRN a buy or a sell?, and where the stock could go from here in the BMRN stock forecast.

For income investors, whether BMRN pays a dividend and how the payout looks is covered in does BMRN pay a dividend? And to weigh BMRN against a peer, read the full side-by-side comparisons: BMRN vs VRTX and BMRN vs REGN.

Wondering how BMRN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BioMarin Pharmaceutical Inc.

Ask Walnut's AI anything about BMRN and see how it fits what you own.

FAQ

What does BioMarin do?

+

BioMarin develops and commercializes therapies for rare genetic diseases. Its portfolio includes enzyme replacement therapies for lysosomal and metabolic disorders, Voxzogo for children with achondroplasia, and, following the 2026 Amicus acquisition, Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease. In September 2026 it added an early-stage hypophosphatasia program through the Alesta acquisition.

How do you invest in BMRN?

+

BMRN trades on the Nasdaq, so you can buy shares through any brokerage account, either as a standalone position or as part of a healthcare or rare-disease themed basket. Some investors also gain exposure indirectly through biotech and healthcare ETFs that hold the stock.

Is BMRN a good investment?

+

That depends on your goals, time horizon and risk tolerance, and Walnut is not an investment adviser. The descriptive picture is a profitable rare-disease specialist with accelerating revenue, concentrated product risk and new competition in achondroplasia, trading near 8 times forward earnings in October 2026, so it is worth weighing the growth drivers against the risks yourself or with a licensed adviser.

What is BioMarin's biggest growth driver?

+

Voxzogo, its treatment for children with achondroplasia, is the fastest-growing product, generating roughly $920 million in 2025. Continued patient additions and potential label expansions such as hypochondroplasia make it central to the 2026 outlook, alongside the newly acquired Amicus products.

How did BioMarin do in its latest quarter?

+

In Q2 2026 BioMarin reported revenue of about $990 million, up roughly 20% year over year with the Amicus products included, and non-GAAP EPS of $1.20 against a $0.95 consensus, a rebound from a Q1 miss. GAAP net income was about $45 million. Q3 2026 results are due October 26, 2026, with consensus near $0.95 EPS on about $1.03 billion of revenue, and the company has flagged a $1.50 hit to Q3 adjusted EPS from the Alesta deal.

How has BMRN stock performed in 2026?

+

As of October 16, 2026, BMRN closed near $55.06, down about 7% year to date and 14% over the past month, and up about 4% over one year. Its 52-week range runs from roughly $49 to $71.

Why did BioMarin acquire Amicus Therapeutics?

+

BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus in April 2026 to broaden its rare-disease portfolio and accelerate revenue growth. The deal added Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease, and management expected it to be slightly dilutive in 2026 and accretive from 2027.

What is the Alesta acquisition?

+

BioMarin closed its acquisition of Alesta Therapeutics on September 1, 2026. Alesta's lead program, ALE1, is an orally active small molecule in a Phase 1/2a trial for hypophosphatasia, a rare genetic bone disease. BioMarin expects $283 million of acquired in-process R&D in Q3, a $1.50 hit to Q3 adjusted EPS and about $1.55 for the full year.

What happened to Roctavian?

+

Roctavian, BioMarin's gene therapy for severe hemophilia A, struggled commercially. After exploring a divestiture and failing to find a qualified buyer, the company decided to voluntarily withdraw Roctavian from the market and recorded an asset write-down, refocusing resources on higher-return programs.

Who are BioMarin's main competitors?

+

Competitors include rare-disease specialists such as Ultragenyx, Alnylam, Sarepta and Vertex, large-cap enzyme and metabolic players like Sanofi, Takeda and AstraZeneca's Alexion unit, and, in achondroplasia specifically, Ascendis Pharma with TransCon CNP and BridgeBio, whose filing received FDA priority review in October 2026.

Does BioMarin pay a dividend?

+

No. BioMarin does not pay a dividend, reinvesting cash flow into research, its pipeline and acquisitions such as the Amicus and Alesta deals. Investors in BMRN have generally been looking for capital appreciation from growth rather than income.

Guides that feature BMRN

BMRN is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with BioMarin Pharmaceutical Inc.'s investor relations page or your broker before making investment decisions.